|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
|
Amneal Pharmaceuticals, Inc. (Name of Issuer) |
Class A Common Stock, par value $0.01 (Title of Class of Securities) |
03168L105 (CUSIP Number) |
Christine Krentz 4 Gatehall Drive, Parsippany, NJ, 07054-4513 949-409-6700 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
11/13/2024 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 03168L105 |
| 1 |
Name of reporting person
Patel Dipan | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
 (a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
23,828,992.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
7.7 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
The percentage of ownership of the Class A Common Stock by the Reporting Person presented in this Statement is based on 309,884,000 shares of Class A Common Stock outstanding, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed on November 11, 2024.
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Class A Common Stock, par value $0.01 |
| (b) | Name of Issuer:
Amneal Pharmaceuticals, Inc. |
| (c) | Address of Issuer's Principal Executive Offices:
400 Crossing Blvd, Bridgewater,
NEW JERSEY
, 08807. |
| Item 4. | Purpose of Transaction |
The disclosure in Item 4 is hereby amended and supplemented by adding the following:
Between July 15 and November 13, 2024, trusts controlled by the Reporting Person sold 3,076,081 shares of Class A Common Stock in open market transactions at prices per share between $6.75 and $9.31. | |
| Item 5. | Interest in Securities of the Issuer |
| (b) | The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by the Reporting Person, as well as the number of shares of Class A Common Stock as to which the Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 309,884,000 shares of Class A Common Stock outstanding, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed on November 11, 2024:
Reporting Person - Dipan Patel
Amount beneficially owned - 23,828,992
Percent of class - 7.7
Sole power to vote or to direct the vote - 23,828,992
Shared power to vote or to direct the vote - 0
Sole power to dispose or to direct the disposition - 23,828,992
Shared power to dispose or to direct the disposition - 0
The Reporting Person may be deemed to beneficially own 23,828,992 shares of Class A Common Stock held of record by trusts controlled by the Reporting Person. |
| (c) | The information set forth in Item 4 of this Amendment No. 3 is incorporated by reference herein. |
| (d) | None. |
| (e) | Not applicable. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|